Erica Lane Smith
Researcher
Formerly Arkansas Affiliated with UAMS through 2021; recent publications list Ambry Genetics (United States).
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Erica Lane Smith's research focuses on the development of small-molecule inhibitors, particularly targeting the RET oncoprotein in lung cancer. Her work investigates novel pyrazoloadenine compounds as potential antineoplastic agents. Smith has explored fragment optimization approaches to discover and refine these inhibitors, with a perspective on their clinical development and potential use in cancer treatment. Her research interests align with drug discovery and development, aiming to identify new therapeutic strategies for neoplasms. Smith collaborates with researchers at the University of Arkansas for Medical Sciences, including Katie R. Ryan and Brendan Frett.
Metrics
- h-index: 2
- Publications: 2
- Citations: 42
Selected Publications
-
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development (2021)
-
Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach (2021)
Collaboration Network
Top Collaborators
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
- Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
Similar Researchers
Based on overlapping research topics